Health Canada has just authorized a made-in-Canada COVID-19 vaccine from a company called Medicago. The two-dose, plant-based vaccine is known as Covifenz and is authorized for use in people aged 18-64. However, Health Canada has said that its effectiveness and safety for the age group has “not yet been established.”
Clinical trials showed the vaccine was 71 per cent effective in protecting against COVID-19 one week after the second dose. The dosing schedule is 21 days apart. Medicago is a biotechnology company based in Quebec City and submitted its Phase 3 data to Health Canada in December.
The data released on December 7 suggests its vaccine candidate was 75.3 per cent effective against the Delta variant. This was after a late-stage study when the patient was enhanced by GlaxoSmithKline’s booster. The company’s vaccine does not use animal products or live viruses like traditional methods.
For more information about the source click HERE